Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 2680 dose-ranging study in narcolepsy type 1
2024-511112-24-00Phase 2Completed
- Sponsor
- Alkermes
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of alixorexton in narcolepsy type 1 (NT1), sponsored by Alkermes. Started Jan 2025; status: completed.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2024-511112-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511112-24-00.